CFR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cullen/Frost Bankers is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The company’s fundamentals are solid and Q1 showed healthy growth, but the technical setup is weak, options sentiment is mixed-to-bearish, and Wall Street is divided with several neutral/sell-equivalent views. Given the current price action and lack of a strong proprietary buy signal, the better call is to hold off rather than buy immediately.
CFR is trading at 138.26, slightly below the prior close of 138.56 and below the pivot level of 142.273. The MACD histogram is -0.68 and expanding negatively, which points to downside momentum. RSI_6 at 33.68 is near oversold but not a clean reversal signal. Moving averages are converging, suggesting the stock is still searching for direction. Support is near 138.682 and then 136.464, while resistance sits at 145.863 and 148.082. Overall trend: weak to neutral, with short-term pressure still present.
["Q1 revenue rose 6.25% YoY", "Q1 net income rose 13.12% YoY", "Q1 EPS rose 15.22% YoY", "Stephens upgraded the stock to Overweight", "Raymond James remains Outperform and highlighted broad-based upside in EPS, PPNR, NII, NIM, loan growth, and credit quality", "Management guidance was viewed by Stephens as conservative, which could leave room for upside surprises"]
["Citi keeps a Sell rating, despite raising its target to 131", "Evercore ISI remains In Line", "DA Davidson remains Neutral", "Current technical momentum is negative with a declining MACD histogram", "No AI Stock Picker signal today", "No SwingMax signal recently", "No meaningful insider, hedge fund, or congress trading support", "News flow provided is not company-specific and does not add a near-term catalyst"]
In 2026/Q1, Cullen/Frost posted solid year-over-year growth. Revenue increased to $538.4M, up 6.25% YoY. Net income rose to $167.2M, up 13.12% YoY. EPS increased to $2.65, up 15.22% YoY. This is a healthy latest-quarter seasonal update, showing improving profitability and earnings growth, which supports the long-term fundamental case.
Recent analyst action is mixed but slightly improving. Stephens upgraded CFR to Overweight and raised its target to $164, while Raymond James maintained Outperform with a $155 target. On the other hand, Citi kept a Sell rating and set a $131 target, Evercore ISI stayed In Line with a $149 target, and DA Davidson remained Neutral at $144. The Wall Street pros view is split: bulls like the company’s defensive quality, organic expansion, and improving earnings outlook, while bears and neutrals point to premium valuation, cost-of-equity concerns, and some credit uncertainty. Net takeaway: sentiment has improved, but conviction is not strong enough for an immediate buy.
